Mesoblast Ltd (MEOBF) 3.5000 $MEOBF
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (-0.23), OSIR: 15.95 (+0.28), GSK: 47.94 (+1.99), ATHX: 2.12 (unch)
Pluristem's Immunotherapy Could Fast-Track GvHD Studies Under Japanese Legislation
Sharon di Stefano - Seeking Alpha - Mon Jan 05, 11:41AM CST
With data in hand that shows evidence its PLX cell therapy produces an immune response, Pluristem Therapeutics (NASDAQ: PSTI ) enters the exploding area of immunotherapy, or treating disease via manipulation of the human immune system, and joins the...
PSTI: 2.91 (+0.01)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
Athersys Could Benefit Immensely From Japan Reimbursement On Stroke
Wall Street Titan - at Seeking Alpha - Wed Nov 26, 7:13AM CST
ATHX: 2.12 (unch)
Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.91 (+0.01), UTHR: 151.11 (+3.59), OSIR: 15.95 (+0.28), ATHX: 2.12 (unch)
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (-0.23), OSIR: 15.95 (+0.28), GSK: 47.94 (+1.99), ATHX: 2.12 (unch)
Pluristem's Immunotherapy Could Fast-Track GvHD Studies Under Japanese Legislation
Sharon di Stefano - Seeking Alpha - Mon Jan 05, 11:41AM CST
With data in hand that shows evidence its PLX cell therapy produces an immune response, Pluristem Therapeutics (NASDAQ: PSTI ) enters the exploding area of immunotherapy, or treating disease via manipulation of the human immune system, and joins the...
PSTI: 2.91 (+0.01)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
Athersys Could Benefit Immensely From Japan Reimbursement On Stroke
Wall Street Titan - at Seeking Alpha - Wed Nov 26, 7:13AM CST
ATHX: 2.12 (unch)
Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.91 (+0.01), UTHR: 151.11 (+3.59), OSIR: 15.95 (+0.28), ATHX: 2.12 (unch)
